Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion

Zaghla, Badeel Kh Q.; Safürek, Zuhal; Gröger, Daniela; Mecklenbräuker, Shima; Lingstädt, Nina-Sophie; Popp, Oliver; Spengler, Johanna; Haji, Mohamed; Montesion, Meagan; Albacker, Lee A.; Mertins, Philipp; Klatt, Martin G.

Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 2MB
	Other (Supplementary Material) 26MB

Item Type:	Article
Title:	Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion
Creators Name:	Zaghla, Badeel Kh Q., Safürek, Zuhal, Gröger, Daniela, Mecklenbräuker, Shima, Lingstädt, Nina-Sophie, Popp, Oliver, Spengler, Johanna, Haji, Mohamed, Montesion, Meagan, Albacker, Lee A., Mertins, Philipp and Klatt, Martin G.
Abstract:	Peptide presentation on human leukocyte antigens (HLAs) is essential for initiating T-cell responses and all consequences of this presentation including anticancer immunity or immune escape. Many studies have relied on in silico prediction tools rather than biological measurement of HLA presentation to study these effects. To better assess the frequency and consequences of neoantigen presentation, we overexpressed 125 combinations of full-length neoantigens and one HLA class I allele to experimentally validate presentation of mutated and non-mutated HLA ligands through HLA ligand isolation followed by tandem mass spectrometry. A successful presentation was observed only in 22% of predicted cases with strong implications on previously described downstream effects. For example, the association of HLA loss of heterozygosity with predicted neoepitopes was challenged for 58% (73/125) of combinations. Furthermore, when testing 51 sequences used for personalized messenger RNA neoepitope vaccines, we observed that clinical responses were independent of the presentation status of the neoepitopes. Even a presumably neoepitope-specific and strongly expanded T cell receptor clone from a neoantigen vaccination study could not be linked to a successfully presented neoepitope. Overall, these data highlight the importance of validating the presentation of neoepitopes to fully understand our interpretation of clinical mutation-specific responses and their related effects, including immune evasion.
Keywords:	Antigen Presentation, Cancer Vaccines, HLA Antigens, Histocompatibility Antigens Class I, Immune Evasion, Neoplasm Antigens, T-Lymphocyte Epitopes, T-Lymphocytes
Source:	Journal for ImmunoTherapy of Cancer
ISSN:	2051-1426
Publisher:	BMJ Publishing Group
Volume:	14
Number:	1
Page Range:	e013271
Date:	January 2026
Official Publication:	https://doi.org/10.1136/jitc-2025-013271
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year